ADMA Biologics Inc is a United States-based biopharmaceutical company. It is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases. The segments of the company are Plasma collection center segment, which includes the company’s operations in Georgia and Research and development segment, which includes the Company’s plasma development operations in New Jersey. The group generates the majority of the revenue from the Plasma collection center segment which includes the sale of human source plasma.